A Diagnostics & Imaging Week

Clinical Data (Newton, Massachusetts), a developer of pharmacogenomics and clinical diagnostics, said it has entered into a collaborative research agreement with the University of Pittsburgh Cancer Institute (UPCI; Pittsburgh).

Clinical Data, acting as the study sponsor, will apply metabolomics analysis to serum samples from a population of patients diagnosed with lung cancer and matched control subjects without lung cancer recruited as part of the National Cancer Institute-funded Specialized Program of Research Excellence (SPORE) in lung cancer at the UPCI. The serum samples will be provided to Clinical Data by the UPCI.

The collaboration will pursue what the company believes is the first metabolomics study in a lung cancer population. The company notes that any new intellectual property or inventions derived from this study will remain the property of the respective party that makes any new discovery, with final ownership determined by applicable U.S. patent law.

HemoSense (San Jose, California) said it has signed a marketing and distribution agreement with ZyCare (Chapel Hill, North Carolina) to integrate the use of Hemo-Sense's INRatio PT/INR Monitoring system with ZyCare's web-based CoagCare system for patient self-testing thro-ugh physician practices and hospital clinics.

INRatio is a portable Prothrombin Time/INR testing monitor, and CoagCare is the only FDA cleared, HIPAA compatible remote INR test reporting and dosage management system for patients on oral anticoagulant therapy.

CoagCare enables patient home monitoring, using INRatio remotely.

Imagin Molecular (Oak Brook, Illinois) reported entering into an agreement with PET Management Services (PMS; Niagara, New York) for bioinformatics research and imaging center management.

PMS will assist Imagin Nuclear Partners (INP) to deliver specialized evidence-based solutions for cardiac diagnostics and treatments using that demonstrates cost savings to insurance companies when cardiac PET is performed on selected patients as a first-line test rather than traditional single photon computed tomography (SPECT) scans.

No Comments